Danny Khalil is an Oncology physician affiliated with Memorial Sloan Kettering Cancer Center. OpenAlex indexes 163 publications with 4,384 citations (h-index 19).
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
Telephone
Practice address and telephone from the federal NPPES registry.
Sign in to view contact details →Industry payments
2 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- ABBVIE INC.Program year20231 payment
- Incyte CorporationProgram year20221 payment
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Metabolism & gastrointestinal
69.3%Serotonin-3 Receptor Antagonist29.8%Ondansetron Hcl68%Ondansetron Odt32%Part D<11 patientsAntidiarrheal microorganisms14.9%Creon100%Part D<11 patients+ 2 more classes in this area
Cancer & immunology
20.2%Isocitrate Dehydrogenase 1 Inhibitor20.2%Tibsovo100%Part D<11 patientsNervous system
10.5%Opioid Agonist10.5%Oxycodone Hcl100%Part D<11 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
NIH funding
1 NIH research award on record, funded 2020–2024 per NIH RePORTER. The latest:
- Local blockade of IL10R on innate immune cells to mediate both innate and adaptive anti-tumor immunity
Sloan-Kettering Inst Can Research
FY2024$263,034K08CA248964 - Local blockade of IL10R on innate immune cells to mediate both innate and adaptive anti-tumor immunity
Sloan-Kettering Inst Can Research
FY2023$263,034K08CA248964 - Local blockade of IL10R on innate immune cells to mediate both innate and adaptive anti-tumor immunity
Sloan-Kettering Inst Can Research
FY2022$263,034K08CA248964
Awards in the NIH RePORTER records where a principal investigator name matches this physician at an organization in their practice state. Latest award years shown; each row links to the project record on RePORTER.
Similar KOLs
Other experts from the same institution or the same specialty.
Howard Scher, MD
Memorial Sloan Kettering Cancer Center
Robert Motzer, MD
Memorial Sloan Kettering Cancer Center
Charles Sawyers, MD
Memorial Sloan Kettering Cancer Center
Mark Kris, MD
Memorial Sloan Kettering Cancer Center
Carl June, MD
University of Pennsylvania
Rainer Storb
University of Washington
Christina Fitzmaurice, MD
Larry Norton, MD
Memorial Sloan Kettering Cancer Center
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments, shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”